NCT05271630

Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 69 (actual)
• Sponsor: H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to determine outcomes for Multiple Myeloma patients on maintenance single agent vs. doublet (IMiD + PI) combination chemotherapy post Autologous Stem Cell Transplant (ASCT).

Detailed description

This non-interventional, cohort prospective research study will assess outcomes for Multiple Myeloma patients on maintenance single agent vs. doublet (IMiD + PI) combination chemotherapy post ASCT.

Conditions

• Multiple Myeloma

Interventions

Type	Name	Description
OTHER	Autologous Stem Cell Transplant	This observational study will compare outcomes of prospectively enrolled ASCT recipients receiving Single agent vs doublet maintenance chemotherapy post ASCT
DRUG	Immunomodulatory Agent	ASCT recipients receiving maintenance therapy consisting of an Immunomodulatory agent (IMID) after ASCT transplant
DRUG	Proteasome Inhibitor	ASCT recipients receiving maintenance therapy with a proteasome inhibitor in combination with an immunomodulatory drug after ASCT transplant

Timeline

• Start date: 2022-04-20
• Primary completion: 2025-12-04
• Completion: 2026-12-01
• First posted: 2022-03-09
• Last updated: 2026-03-02

Locations

1 site across 1 country: United States